Status:
WITHDRAWN
Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota
Lead Sponsor:
University of Minnesota
Conditions:
Covid19
SARS-CoV Infection
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this epidemiologic study is to estimate the prevalence and incidence of anti-SARS-CoV-2 antibodies in at-risk, exposed, affected populations. The study will also estimate the risk of SA...
Detailed Description
This study is not for real-time diagnostic purposes, guidance for patient care, or the development of a diagnostic test. The research tests performed for this study will not be prioritized over clinic...
Eligibility Criteria
Inclusion
- Participants in Group 1 (General Healthy Population) must have no known exposure to SARS-CoV-2 and have not sought medical help in the previous 4 months for SARS-CoV-2-related symptoms
- Participants in Group 2 must be currently enrolled in a medical residency program
- Participants in Group 3 must currently test positive for HIV infection
Exclusion
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data (e.g., someone not able to answer the questionnaire because of a psychological condition or an anxiety disorder that is severe).
- Contraindication for routine blood draws (e.g., severe anemia, hemophilia, etc)
Key Trial Info
Start Date :
July 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04473183
Start Date
July 21 2020
End Date
January 1 2022
Last Update
August 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455